
CCRN Stock Forecast & Price Target
CCRN Analyst Ratings
Bulls say
Cross Country Healthcare is experiencing a positive outlook due to a projected inflection point in its largest segment, travel nurse staffing, driven by improving market demand and recent managed service provider contract wins. In Q4/24, the company achieved revenue of $309.9 million, reflecting strong performance in its non-travel segments and aligning with the high end of guidance, contributing to a total revenue of slightly more than $2.0 billion for 2023. Additionally, the acquisition agreement by Aya Healthcare for $18.61 per share, representing a 67% premium, underscores the market's confidence in Cross Country's ongoing value and growth potential.
Bears say
Cross Country Healthcare experienced a significant revenue decline of 25% year-over-year, attributed to continued softer demand conditions in the healthcare travel staffing industry. The company reported a substantial drop in adjusted EBITDA, down 55% year-over-year to $9.3 million, with ongoing pressure on gross margins due to competitive pricing and reduced demand for contingent labor. Additionally, the company's 2025 estimates have been notably lowered, with projected revenue decreased to $1.255 billion and adjusted EBITDA estimates scaled back to $39.2 million, reflecting a conservative outlook on the recovery in the travel staffing sector.
This aggregate rating is based on analysts' research of Cross Country Healthcare and is not a guaranteed prediction by Public.com or investment advice.
CCRN Analyst Forecast & Price Prediction
Start investing in CCRN
Order type
Buy in
Order amount
Est. shares
0 shares